Citations

Clear

415 citation(s) found for "Snyder, D".

Reassessing the Risk of Esophageal Cancer in Achalasia Post‐Therapy: Findings From a Large United States Multi‐Centre Retrospective Propensity‐Matched Cohort Study
Perananthan, Varan , Mohammed, Mouhand F., Hamid, Osama , Codipilly, Don C. , Snyder, Diana L. , Leggett, Cadman L. , Alexander, Jeffrey A. , Vela, Marcelo F. , Leggett, Cadman, Vela, Marcelo F , Leggett, Cadman L , Perananthan, Varan , Mohammed, Mouhand F., Beran, Azizullah , Ravi, Karthik

Mayo Clinic

Neurogastroenterology & Motility | September 1, 2025 | Volume: 37 | Issue: 11 | Pages: No page available

10.1111/nmo.70151 | PMID 40887794 Get It

ABSTRACTBackgroundAchalasia is associated with an increased risk of esophageal cancer; though reported incidence rates vary widely (0.4% to 9.2%) due to differences in demographics, follow‐up duration, and diagnostic methods. This study evaluates the risk of esophageal cancer and Barrett's esophagus (BE) in achalasia using a large national database and a propensity‐matched control cohort.MethodsAchalasia patients were identified utilizing the TriNetX database based on International Classification of Diseases (ICD) and Current Procedural Terminology (CPT) codes for diagnostic procedures and lower esophageal sphincter (LES) directed therapies, including Heller myotomy, peroral endoscopic myotomy, and pneumatic dilation. A matched control group of celiac disease patients was used. A 1‐year lead time was applied to exclude secondary malignant achalasia. Outcomes included the incidence of esophageal cancer and BE, with subgroup analysis in patients following therapy.ResultsAmong 7863 achalasia patients (mean age 58.0, 51.9% female), the esophageal cancer risk was significantly higher than control (risk ratio 2.87, 95% CI: 1.56–5.27, p < 0.001). The absolute risk was low, with 40 cases (0.51%) over a mean follow‐up of 3.18 years. BE risk was also higher in achalasia (risk ratio 1.54, 95% CI: 1.24–1.90, p < 0.001), with 220 cases (2.80%). Subgroup analysis revealed no significant difference in BE risk between POEM and Heller myotomy (risk ratio 1.0, 95% CI: 0.42–2.40, p > 0.99).DiscussionThe elevated cancer risk in achalasia over a short follow‐up period warrants reconsideration of current endoscopic surveillance guidelines, despite the low absolute risk of esophageal cancer and BE.
Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Sekela, Michael , Snyder, Edward L. , Toyoda, Yoshiya , Alsammak, Mohamed , Sodha, Neel R. , Beaver, Thomas M. , Pelletier, J. Peter R. , Gorham, James D. , McNeil, John W. , Pearl, Ronald G. , Nuttall, Gregory A. , Reece, T. Brett , Collaborators, and the ReCePI Study, Sekela, Michael E , Welsby, Ian J , Alsammak, Mohamed , Sodha, Neel R , Beaver, Thomas M , Pelletier, J Peter R , Gorham, James D , McNeil, John S , Sniecinski, Roman M , Nuttall, Gregory A , Sarode, Ravi , Benjamin, Richard J , Collaborators, and the ReCePI Study

Mayo Clinic

Anesthesiology | August 12, 2025 | Volume: 143 | Issue: 5 | Pages: 1196-1210

10.1097/aln.0000000000005716 | PMID 41085306 Get It

Background: Transfusion has a persistent low risk of transfusion-transmitted infection and transfusion-associated graft- versus -host disease that may be addressed using pathogen reduction. The Red Cell Pathogen Inactivation (ReCePI) trial tested whether amustaline/glutathione pathogen-reduced red cells are noninferior to conventional transfusions for support of acute surgical blood loss. Methods: A phase 3, double-blinded, noninferiority trial randomized cardiac or thoracic–aorta surgery patients with increased risk of red cell transfusion to receive pathogen-reduced or conventional red cells during and for 7 days postsurgery. The primary endpoint was the proportion of patients with acute kidney injury (AKI), which is defined as an increase from baseline of greater than or equal to 0.3 mg/dl serum creatinine within 48 h of surgery. Noninferiority was claimed if the upper bound 95% CI of the treatment difference was less than half (50%) of the observed conventional arm incidence. Adverse events and treatment-emergent red cell antibodies were assessed for 28 and 75 days, respectively. Results: A total of 581 subjects were randomized, and 321 (55%) were transfused with study red cells. Transfused subjects in both arms had similar baseline demographics, medical histories, hemoglobin levels, and surgical procedures. Hemoglobin day 3 nadir levels (8.6 g/dl [7.8 to 9.2] in the pathogen-reduced arm; 8.4 g/dl [7.8 to 9.3] in the conventional arm; P = 0.52) were comparable. Incidence of AKI by 48 h was 46 of 157 (29.3%) in the pathogen-reduced arm and 45 of 161 (28.0%) in the conventional arm (treatment difference, 0.7%; 95% CI, −8.9 to 10.4%; noninferiority margin, 14.0%; P = 0.001 for noninferiority). AKI within 7 days by Kidney Disease Improving Global Outcomes staging criteria was not different (59 of 159 [37.1%] in the pathogen-reduced arm; 55 of 162 [34.0%] in the conventional arm; P = 0.53), but stage III was more common in the pathogen-reduced arm (pathogen-reduced arm, 15 of 159 [9.4%]; conventional arm, 7 of 162 [4.3%]; P = 0.075). Of 159 pathogen-reduced red cell recipients, 5 (3.1%) developed specific, low-titer antibodies without evidence of hemolysis. Conclusions: The incidence of AKI in recipients of pathogen-reduced red cells was noninferior to conventional red cell transfusion. Treatment-emergent antibodies were uncommon and not clinically significant.
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
Carrillo, Marı́a C., Chen, Christopher , Choi, Seong Hye , Fontana, Igor C. , Graff‐Radford, Jonathan, Heidebrink, Judith L. , Hu, Chaur‐Jong , Ihara, Ryoko , Ip, Fanny C.F., Fitri, Fasihah Irfani , Jack, Clifford R. , Yoon, Soo Jin , Jia, Jianping , Kandiah, Nagaendran, Kowa, Hisatomo , Joie, Renaud La , Noritake, Ryoji, Okonkwo, Ozioma C. , Raman, Rema , Shen, Yong , Simuni, Tanya, Snyder, Heather M. , Sriwannopas, Orapitchaya, Wang, Huali , Zhou, Jin , Sexton, Claire E. , Carrillo, María C. , Simuni, Tanya , Chen, Christopher , Mahinrad, Simin , Jack, Clifford R , La Joie, Renaud , Simuni, Tanya , Iwatsubo, Takeshi , Sperling, Reisa Anne , Algeciras‐Schimnich, Alicia , Arai, Hidenori , Barron, Anna M. , Benzinger, Tammie L.S. , Graff‐Radford, Jonathan , Grill, Joshua D. , Ikeuchi, Takeshi , Iwata, Atsushi , Kandiah, Nagaendran , Kim, SangYun , Niimi, Yoshiki , Palmqvist, Sebastian , Rafii, Michael S. , Stoeckel, Luke E. , Flier, Wiesje M. van der , Wilcock, Donna M. , Zetterberg, Henrik , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia | August 5, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70536 | PMID 40760693 Get It

Abstract The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease‐modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment‐induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non‐pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker‐based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic‐specific impacts, focusing on Asia.
Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT‐AD)
Mastrolorenzo, Margaret D., Snyder, Heather M. , Carrillo, María C. , Petersen, Ronald C. , Aisen, Paul , Sperling, Reisa, Hussen, Kedir, Raman, Rema , Grill, Joshua D. , Mastrolorenzo, Margaret D., Sperling, Reisa Anne , Hussen, Kedir

Mayo Clinic

Alzheimer's & Dementia | July 15, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70441 | PMID 40660743 Get It

Abstract BACKGROUND First held in 2020, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT‐AD) is a program to train the next generation of Alzheimer's disease (AD) and related dementias (AD/ADRD) clinical trialists. METHODS IMPACT‐AD includes didactic, workshop, and small group components. RESULTS IMPACT‐AD has trained 18 alumni–scholars (accepted from 424 applicants), of whom 67% were female. Forty‐eight (26%) were the first in their family to attend college. Scholars included individuals from all racial and ethnic groups. Each year, participants demonstrated increased learning about AD/ADRD clinical trials through a pre/post‐test model of knowledge assessments. Among those completing annual follow‐up surveys, >84% remain in AD/ADRD trials careers, and 80% have experienced career advances or milestones. In the latter group, > 90% indicated that participating in IMPACT‐AD contributed to this career growth. DISCUSSION IMPACT‐AD is a novel educational program that is achieving its goals. Highlights Over 5 years, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT‐AD) has trained 188 scholars. The course has been accessible to a broad range of trainees who were diverse in professional and demographic backgrounds. Objective assessments indicate that participants gain knowledge through participation. Eighty‐four percent of trainees have remained in Alzheimer's disease and related dementias (ADRD) trials careers. Eighty percent of alumni have experienced career advances; nearly all indicated that participating in the course contributed to their success.
Functional Lumen Imaging Probe as Part of Multimodality Assessment of Esophagogastric Junction Opening Is Important in Longitudinal Follow‐Up of Patients With Treated Achalasia
Kamboj, Amrit K. , Sood, Shubham , Truong, Brandon , Song, Louis M. Wong Kee , Wells, Michael , Wigle, Dennis A. , Codipilly, Don C. , Snyder, Diana L. , Alexander, Jeffrey A., Leggett, Cadman L. , Lennon, Ryan J. , Koop, Andree , Vela, Marcelo F. , Wigle, Dennis, Vela, Marcelo F , Leggett, Cadman L , Alexander, Jeffrey A., Ravi, Karthik

Mayo Clinic

Neurogastroenterology & Motility | July 15, 2025 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/nmo.70121 | PMID 40660739 Get It

ABSTRACT Background Functional lumen imaging probe (FLIP) utility is established in treatment‐naïve achalasia but less clear following lower esophageal sphincter (LES) directed therapy. Methods Achalasia patients with LES directed therapy across three tertiary care centers between 2017 and 2024 with post‐treatment FLIP and timed barium esophagram (TBE) were retrospectively identified. Reduced esophagogastric junction (EGJ) opening was defined by distensibility index (DI) < 2 mm 2 /mmHg and diameter < 12 mm. Abnormal emptying on TBE was defined as column height ≥ 5 cm at 5 min and/or retained tablet. Eckardt scores ≤ 3 defined clinical response. Key Results The study included 222 patients (46% peroral endoscopic myotomy, 46% laparoscopic Heller myotomy, 8% pneumatic dilation) with a median of 1.4 years to post‐treatment TBE/FLIP. Abnormal emptying on TBE was associated with a narrower median EGJ diameter (13.2 vs. 14.8 mm, p = 0.008), a greater frequency of EGJ diameter < 12 mm (36% vs. 21%, p = 0.012), and a smaller change in EGJ diameter (+4.6 vs. +8.6 mm, p = 0.002). Abnormal emptying on TBE occurred more frequently in patients with EGJ DI < 2 mm 2 /mmHg (8.5% vs. 2.6%, p = 0.052), but was not associated with median EGJ DI (4.5 vs. 5.1 mm 2 /mmHg, p = 0.29) nor median change in EGJ DI (+2.9 vs. +3.9 mm 2 /mmHg, p = 0.25). Patients with reduced EGJ DI or EGJ diameter more often had abnormal TBE (37% vs. 22%, p = 0.012). Only the change in DI (+3.8 vs. +1.5 mm 2 /mmHg, p = 0.012) and diameter (+8.2 vs. +1.6 mm, p = 0.002) on FLIP was associated with a clinical response based on Eckardt ≤ 3. Conclusions and Inferences FLIP following achalasia therapy generally correlates with TBE, although discrepant findings are not uncommon. In particular, FLIP EGJ‐diameter has a strong association with esophageal emptying on TBE. Both TBE and FLIP have limited association with clinical response based on Eckardt, with change in DI and diameter on FLIP most strongly associated. Consequently, FLIP as part of multimodal assessment appears useful in the longitudinal follow‐up of treated achalasia.
Impact of Providing an Automated Telephone Option to Report Weekly Patient-Reported Outcome Measures in the PRO-TECT Trial (AFT-39) on Disparity Gaps in Symptom Management and Outcomes
Stover, Angela M. , Deal, Allison M. , Ginos, Brenda, Dueck, Amylou C. , Spears, Patricia A. , Jansen, Jennifer , Carr, Philip, Henson, Sydney, Bennett, Antonia V. , Jönsson, Mattias , Snyder, Claire , Basch, Ethan , Dueck, A. C. , Bennett, Antonia V , Stover, Angela M , Jonsson, Mattias , Jansen, Jennifer , Snyder, Claire , Deal, Allison , Basch, Ethan

Mayo Clinic

JCO Clinical Cancer Informatics | May 23, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/cci-25-00046 | PMID 40408610 Get It

PURPOSE Many trials ask patients to complete patient-reported outcome measures (PROMs) via the web, excluding patients unable to use/access the Internet. The PRO-TECT trial (AFT-39, ClinicalTrials.gov identifier: NCT03249090 ) also offered a telephone interface option (interactive voice response [IVR]). We compared patients choosing IVR versus web on alert rates to nurses and clinical outcomes to determine if a telephone option can close disparities in symptom management. METHODS PRO-TECT randomized 26 community oncology practices to the PROM intervention arm where concerning symptoms generated automated alerts to nurses. IVR and web patients were compared for social determinants of health (SDOH) using analysis of variance and chi-square tests. After accounting for clustering and confounders, we used generalized estimating equations to compare alert rates, mixed models for quality of life (QOL) at 3 months, and Cox regression for emergency visits and survival at 12 months. RESULTS Among 593 patients, 215 (36%) chose IVR and 378 (64%) chose web. IVR patients were older (65.2 v 60.8 years) and were more often rural residents (32% v 23%), Black (27% v 11%), and with less education (54% v 27% ≤high school; all P < .01). Patients choosing IVR had more surveys with concerning symptoms (49% v 37%) and nurses felt clinical attention was warranted more often (4.8 surveys v 3.4 surveys; all P < .001) but ultimately experienced similar benefits as web in QOL, emergency visits, and survival. CONCLUSION One third of community patients choose a telephone option over the web for reporting PROMs during cancer care. These patients are disproportionately from SDOH backgrounds at risk of poor clinical outcomes and have higher symptom management needs but ultimately experience similar clinical benefits as patients choosing the web. PROM programs should offer web alternatives to close disparities in symptom management.
Spatial Transcriptomics Identify Region-specific Pathogenesis of Bronchiolar and Alveolar Disease in Primary Ciliary Dyskinesia Lungs
Saito, Minako , Murano, Hiroaki , Gilmore, Rodney C. , Cruz, Gabriela De la , Chua, M. , Khoór, András , McCall, Shannon J. , Snyder, Laurie D. , Sembrat, John , Askin, Fred, Shoemark, Amelia , Livraghi-Butrico, A., Randell, S.H., Boucher, R. C. , Asakura, Takanori , Dang, Hong , Okuda, Kenichi , Markovetz, Matthew R. , Brody, Steven L. , Livraghi-Butrico, Alessandra , O’Neal, Wanda K.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7931-A7931

10.1164/ajrccm.2025.211.abstracts.a7931 Get It

Abstract Rationale: Primary ciliary dyskinesia (PCD) is a heterogeneous, rare genetic disorder characterized by dysfunctional motile cilia. PCD pulmonary manifestations include impaired airway mucociliary clearance, mucus obstruction, recurrent infection, and bronchiectasis (BE). Notably, thoracic imaging studies indicate that alveolar atelectasis is more prevalent in children with PCD than in age-matched children with cystic fibrosis (CF). However, morphologic and molecular analyses of the site of initiation and progression of PCD airway disease and relationships to PCD alveolar disease have not been reported. In this study, we analyzed region-specific morphologic and molecular characterizations of airway epithelia and alveolar regions in PCD lungs excised at transplantation to address these questions. Methods: Nine PCD lungs and seven non-diseased control lungs were included in the morphometric studies. Bronchi and proximal and distal bronchioles were defined using unique morphologic structures, and distal airway secretory cell (DASC) markers were used to differentiate between proximal and distal bronchioles. Morphologic characteristics of airway epithelia and luminal mucus were quantitated by histology, immunohistochemistry, and RNA in situ hybridization. Spatial transcriptomic technologies (GeoMx) characterized region-specific transcript expression in three airway epithelial regions (bronchi, proximal bronchioles, and distal bronchioles), intraluminal mucus plugs, and alveolar regions of PCD compared to control lungs. Finally, pulmonary function data from a cohort of PCD subjects were analyzed to investigate correlations between alveolar morphologic findings and alveolar gas exchange function, i.e. diffusing capacity for carbon monoxide (DLCO). Results: PCD bronchi and proximal bronchioles exhibited ectasia, characterized by increased MUC5AC and MUC5B-producing cells, mucus plugs containing MUC5AC and MUC5B mucins infiltrated by neutrophils, and epithelial gene signatures associated with ectasia. In contrast, PCD distal bronchioles were not ectatic and exhibited MUC5B-dominant DASCs, mucus plugs containing selectively MUC5B mucin infiltrated by mixture of neutrophils and macrophages, and gene signatures suggestive of impaired ciliogenesis. Molecular analysis revealed upregulation of pathways associated with muco-inflammation, antimicrobial defense, and the innate immune system routinely in PCD airway epithelia. IL-1β gene signatures were observed in both PCD airway and alveolar epithelia, whereas interferon-stimulated gene signatures were restricted to airway epithelia. Transcriptomic and morphologic analyses suggested that PCD alveolar disease was initiated by distal bronchiolar obstruction, associated with chronic microatelectasis, progressive loss of alveolar epithelial type 2 (AT2) cells, and eventual non-resolving fibrosis. A significant percentage (28%) of people with PCD exhibited reduced DLCO. Conclusions: PCD airway disease is manifest by distinct profiles of proximal vs distal bronchiolar disease associated with microatelectatic and fibrotic alveolar disease.
Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
Memel, Molly , Staffaroni, Adam M. , Ilan‐Gala, Ignacio, Castro, J. García , Kornak, John , Tartaglia, Carmela M., Saloner, Rowan, Cadwallader, Claire J. , Chen, Coty , Gorno‐Tempini, Maria Luisa , Mandelli, Malu, Apostolova, Liana , Graff-Radford, N. R., Pressman, Peter , Miyagawa, Toji , Mackenzie, Ian R. , Darby, R. Ryan , Petrucelli, Len, Gendron, Tania, Heuer, Hilary W. , Forseberg, Leah K., Brushaber, Nellie, Domoto‐Reilly, Kimiko , Ghoshal, Nupur , Pascual, Belén , Lee, Suzee, Ramos, Eliana Marisa , Rademakers, Rosa , Rascovsky, Katya, Masdeu, Joseph C. , Boxer, Adam L., Rosen, Howard J. , Casaletto, Kaitlin B. , Illán‐Gala, Ignacio , Graff-Radford, Neil, Boeve, Brad F, Pascual, Belen , Domoto-Reilly, Kimiko , Garcia Castro, Jesús , Illán-Gala, Ignacio , Saloner, Rowan , VandeBunte, Anna M. , Paolillo, Emily W. , Litvan, Irene , Bayram, Ece , Goldman, Jill , Appleby, Brian S. , Gendron, Tania F. , Rojas, Julio C. , Boeve, Bradley F. , Lapid, Maria I. , Ramanan, Vijay K. , Pantelyat, Alexander , Masdeu, Joseph C , Snyder, Allison , Boxer, Adam L.

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14630 | PMID 40277077 Get It

Abstract INTRODUCTION Sex differences are apparent in neurodegenerative diseases but have not been comprehensively characterized in frontotemporal dementia (FTD). METHODS Participants included 337 adults with autosomal dominant FTD enrolled in the ALLFTD Consortium. Clinical assessments and plasma were collected annually for up to 6 years. Linear mixed‐effects models investigated how sex and disease stage are associated with longitudinal trajectories of cognition, function, and neurofilament light chain (NfL). RESULTS While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. In asymptomatic participants, the association between baseline NfL and clinical trajectories was weaker in females versus males, a difference that was not present in symptomatic participants. DISCUSSION In genetic FTD, females show cognitive resilience in early disease stages followed by steeper clinical declines later in the disease. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD‐causing mutations. Highlights Females with genetic FTD exhibit overall steeper increases in plasma neurofilament light chain (NfL) than males. Females with genetic FTD outperform NfL levels in asymptomatic stages compared to males. Once symptomatic, females with genetic FTD decline more rapidly than males. Plasma NfL is a stronger prognostic marker in asymptomatic males than females.
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries
Harris, Anne K. , Nelson, Alexander T. , Watson, Dave , Mallinger, Paige, Stering, Allen I., Snyder, Stacy L., Levy, Carolyn Fein , Kamihara, Junne , Herzog, Cynthia E. , Lagmay, Joanne , Foresto, Steve, Young, Robert H. , Dehner, Louis P. , Tadavarthy, Anil K., Stall, Jennifer N., Billmire, Deborah F., Schneider, Dominik T. , Schultz, Kris Ann P. , Kamihara, Junne , Chen, Kenneth S , Devins, Kyle M , Schneider, Dominik T , Schultz, Kris Ann P , Levy, Carolyn Fein , Harris, Anne K , Messinger, Yoav H. , Frazier, A Lindsay , Chen, Kenneth , Devins, Kyle M. , Hill, Dana Ashley

Mayo Clinic

Cancer | April 23, 2025 | Volume: 131 | Issue: 9 | Pages: No page available

10.1002/cncr.35862 | PMID 40267023 Get It

AbstractBackgroundOvarian juvenile granulosa cell tumors (juvGCT) are rare sex cord‐stromal tumors that occur primarily in children and adolescents. This study summarizes the clinical presentation and outcomes of patients with juvGCT.MethodsPatients were enrolled in the International Ovarian and Testicular Stromal Tumor and/or International Pleuropulmonary Blastoma/DICER1 Registries. Available medical records were abstracted, and pathology was centrally reviewed. Surgical staging was classified using the 2014 International Federation of Gynecology and Obstetrics (FIGO) criteria.ResultsIn total, 70 patients with juvGCT enrolled and were diagnosed between 2001 and 2024; most patients (81%, 57 of 70) presented with FIGO stage I disease. Adjuvant chemotherapy was given in 30% (21 of 70); all regimens were platinum‐based. Three‐year event‐free survival among patients with stage IA tumors was 80.2% (95% confidence interval [CI], 62.4%–100.0%), IC1 was 87.4 (95% CI, 72.4%–100.0%), IC2‐IC3 was 63.6% (95% CI, 40.7%–99.5%), and II‐IV was 48% (95% CI, 24.6%–93.8%). Of the patients with recurrent juvGCT with known mitotic index (MI), all had MI greater than 19 mitoses per 10 high power fields (HPF) at diagnosis.ConclusionOutcomes were worse for patients with FIGO stage ≥IC2 disease and for tumors with >19 mitoses per 10 HPF. Given the prognostic significance of MI, the authors strongly recommend the assessment of MI for all juvGCTs. More information about tumor biology is critical to identify which patients may benefit from adjuvant chemotherapy and to facilitate the development of novel therapies.